Andrew J. Murphy, EVP Research at REGENERON PHARMACEUTICALS, INC. (REGN), sold 25,718 shares at $968.20 ($24.8M) on 2024-03-14, disclosed to the SEC on 2024-03-15.
Scheduled sale ($24.8M) by EVP Research under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $971.82 | 14,217 | $13.8M | 55.7% |
| 2 | $951.92 | 182 | $173K | 0.7% |
| 3 | $951.92 | 182 | $173K | 0.7% |
| 4 | $952.40 | 444 | $423K | 1.7% |
| 5 | $952.40 | 444 | $423K | 1.7% |
| 6 | $953.77 | 576 |
| $549K |
| 2.2% |
| 7 | $953.77 | 576 | $549K | 2.2% |
| 8 | $954.66 | 870 | $831K | 3.3% |
| 9 | $954.66 | 870 | $831K | 3.3% |
| 10 | $955.54 | 545 | $521K | 2.1% |
| 11 | $955.54 | 545 | $521K | 2.1% |
| 12 | $956.34 | 1,108 | $1.1M | 4.3% |
| 13 | $956.34 | 1,108 | $1.1M | 4.3% |
| 14 | $957.35 | 730 | $699K | 2.8% |
| 15 | $957.35 | 730 | $699K | 2.8% |
| 16 | $958.34 | 477 | $457K | 1.8% |
| 17 | $958.34 | 477 | $457K | 1.8% |
| 18 | $959.36 | 512 | $491K | 2.0% |
| 19 | $959.36 | 512 | $491K | 2.0% |
| 20 | $961.74 | 47 | $45K | 0.2% |
| 21 | $962.87 | 1 | $963 | 0.0% |
| 22 | $965.51 | 78 | $75K | 0.3% |
| 23 | $965.51 | 78 | $75K | 0.3% |
| 24 | $966.30 | 17 | $16K | 0.1% |
| 25 | $968.20 | 196 | $190K | 0.8% |
| 26 | $968.20 | 196 | $190K | 0.8% |
| Total | $964.94 avg | 25,718 | $24.8M | 100% |
| Filing → |
| REGN | SELL | 2023-12-06 | $10.6M | — | Filing → |
| REGN | SELL | 2023-11-15 | $10.3M | — | Filing → |
| REGN | SELL | 2022-11-16 | $5.2M | — | Filing → |